Every material Form 8-K CHINA PHARMA HOLDINGS, INC. has filed with the SEC since February 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
China Pharma Holdings agreed on July 22, 2026 to sell 2,500,000 shares of common stock at $2.00 per share, for gross proceeds of $5 million before fees and expenses, with closing expected around July 23, 2026. The company said it intends to use the net proceeds for working capital and general corporate purposes, but the sale adds new shares and includes investor participation rights and restrictions on future financings that shareholders should weigh.
Offering: 2,500,000 shares at $2.00 per share, for gross proceeds of $5 million
Placement agent FT Global Capital, Inc. receives a cash fee of 7.0% of aggregate proceeds
Investor may participate in up to 40% of subsequent financings for three months after closing
Company agreed not to enter new subsequent placements or Variable Rate Transactions until the 91st day after closing
On February 26, 2026, subsidiary Hainan Helpson Medical & Biotechnology agreed to acquire the ownership of an invention patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang. The $6.93 million transfer price will be paid in company common stock at $0.55 per share, meaning the company is to issue 12,600,000 restricted shares that are not registered under the Securities Act.
Agreement dated February 26, 2026, between subsidiary Helpson and Xiaoyan Zhang, a technology transfer covering an invention patent for sublingual tablets
Transfer price of $6.93 million, paid in common stock at $0.55 per share
Company to issue an aggregate of 12,600,000 restricted shares, offered under the Regulation S exemption to a non-U.S. person in an offshore transaction
Transferor or a designated third party will provide technical services, including product research and development and registration support
On February 5, 2026, subsidiary Hainan Helpson Medical & Biotechnology entered a Technology Transfer Agreement with Xiaoyun Chen to acquire ownership of an invention patent for a Topiroxostat nanoemulsion. The transfer price is $8.82 million, paid in restricted common stock at $0.70 per share, and the closing is expected by February 20, 2026. The share issuance will add 12,600,000 shares to the company's common stock outstanding.
Transfer price of $8.82 million, paid in common stock at $0.70 per share
Company is to issue 12,600,000 restricted shares of common stock
Closing expected by February 20, 2026
Shares are unregistered and issued under Regulation S to a non-U.S. person
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CHINA PHARMA HOLDINGS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →